Cargando…
The antifibrotic drug pirfenidone inhibits spondyloarthritis fibroblast-like synoviocytes and osteoblasts in vitro
BACKGROUND: The pathogenesis of spondyloarthritis (SpA) involves both inflammation and new bone formation in the spine. In line with this, the disease has been characterized as both inflammatory and fibrotic. The current treatment dampens inflammation while new bone formation can progress. Therefore...
Autores principales: | Stougaard, Julie, Lomholt, Søren, Ommen, Pernille, Kelsen, Jens, Kragstrup, Tue W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390625/ https://www.ncbi.nlm.nih.gov/pubmed/30886983 http://dx.doi.org/10.1186/s41927-018-0040-9 |
Ejemplares similares
-
Phenotypic and functional characterization of synovial fluid-derived fibroblast-like synoviocytes in rheumatoid arthritis
por: Køster, Ditte, et al.
Publicado: (2021) -
Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation
por: Vu, Tuong N., et al.
Publicado: (2019) -
Antifibrotic Effects of Caffeine, Curcumin and Pirfenidone in Primary Human Keratocytes
por: Talpan, Delia, et al.
Publicado: (2023) -
Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis
por: Komiya, Chikara, et al.
Publicado: (2017) -
Pharmacological basis of the antifibrotic effects of pirfenidone: Mechanistic insights from cardiac in-vitro and in-vivo models
por: Sartiani, Laura, et al.
Publicado: (2022)